STACK IMAGE - RESEARCH BUNDLE · 2 COMPOUNDS
Somatotropic Research Bundle
CJC-1295 wo DAC + Tesamorelin
CJC-1295 wo DAC10mg£49.99Tesamorelin15mg£129.99
£179.98
£99.98
SAVE 44%
View stack →
- Growth
Tesamorelin Growth Hormone Releasing Factor Analogue
For in vitro research use only. Tesamorelin is not for human or veterinary consumption, diagnosis, treatment, or prevention of any condition.
Tesamorelin is a synthetic version of GHRH (Growth Hormone-Releasing Hormone - the signal the brain uses to trigger growth hormone production). Structural modifications have been added to slow how quickly it breaks down in the body, giving it a longer active window. Research has investigated its effects on GH (growth hormone) and IGF-1 (a related signalling protein) levels, and studies have examined its influence on fat distribution around the abdominal area in animal models.
- CAS Number
- 218949-48-5
- Molecular Formula
- C₂₂₁H₃₅₆N₆₄O₆₈S
- HPLC Purity
- ≥99% (batch-verified)
- Form
- Lyophilised powder
- Storage
- 2–8°C, desiccated, protected from light
- Classification
- Research reagent - in vitro use only
≥99%
HPLC purity
3rd-Party Tested
Independent lab
CoA Every Order
Batch-specific
Tracked 24
Royal Mail UK
Pay by Bank
No card stored
Tesamorelin research overview
Tesamorelin is a 44-amino-acid synthetic analogue of full-length endogenous Growth Hormone Releasing Hormone (GHRH(1-44)), modified at the N-terminus with a trans-3-hexenoic acid conjugate to improve metabolic stability relative to native GHRH. Unlike CJC-1295 wo DAC — which corresponds only to the shorter GHRH(1-29) fragment — Tesamorelin encompasses the complete natural GHRH sequence, providing a research tool that more closely approximates the endogenous hormone’s structure. The N-terminal modification extends its half-life in experimental conditions while preserving the primary GHRH receptor binding interaction.
Preclinical and clinical research on Tesamorelin has focused on two principal areas: growth hormone secretagogue biology and visceral adipose tissue metabolism. As a GHRH receptor (GHRHR) agonist, Tesamorelin stimulates GH release from anterior pituitary somatotroph cells. Research examining the metabolic consequences of GH elevation via Tesamorelin has particularly focused on visceral adipose tissue — the metabolically active fat deposited around abdominal organs — with studies examining effects on adipocyte lipolysis, circulating lipid markers (triglycerides, LDL, HDL), and lean mass and adipose tissue distribution parameters in animal models.
Tesamorelin is also studied in the context of downstream IGF-1 (Insulin-like Growth Factor 1) signalling and in neurological research examining whether GHRH receptor agonism affects cognitive and CNS function markers in preclinical models, building on evidence that GH and IGF-1 receptors are expressed in hippocampal tissue. Its full-length GHRH sequence makes it a useful comparator with truncated GHRH analogues in studies examining receptor occupancy, activation kinetics, and downstream signalling profiles. Velox Peptides supplies Tesamorelin at ≥99% HPLC-verified purity as a lyophilised research reagent. Not for human or veterinary consumption.
Summary paraphrased from the peer-reviewed preclinical literature. For in vitro research use only. For source citations, email support@veloxpeps.com.
📖 Tesamorelin Research Hub
Compound specifications
| Common name | Tesamorelin |
|---|---|
| Full name | Growth Hormone Releasing Factor Analogue |
| CAS number | 218949-48-5 |
| Molecular formula | C₂₂₁H₃₅₆N₆₄O₆₈S |
| Molecular weight | 5195.8 g/mol |
| Sequence | trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2 |
| HPLC purity | ≥99% (batch-verified) |
| Appearance | White to off-white lyophilised powder |
| Solubility | Bacteriostatic water, sterile saline |
| Storage (lyophilised) | 2–8°C, protected from light |
| Storage (reconstituted) | 2–8°C, up to 28 days |
| Supplied as | 15mg |
Batch testing and certificate of analysis
Every batch of Tesamorelin is third-party HPLC-tested prior to dispatch. Batch documentation is available on request.
Previous batch CoAs are archived in the CoA library. For batch-specific CoA requests prior to purchase, contact support@veloxpeps.com.
Stacks containing Tesamorelin
Related compounds
Frequently Asked Research-Use Questions
What purity is Velox Peptides Tesamorelin?
Tesamorelin is supplied at ≥99% HPLC-verified purity. Batch documentation is available on request.
How is Tesamorelin supplied and reconstituted for research use?
Tesamorelin is supplied as a lyophilised powder in sterile single-use vials. For in vitro research use, reconstitution is performed with bacteriostatic water. See the reconstitution calculator for volume calculations based on required concentration.
What is Tesamorelin used for in preclinical research?
Tesamorelin is studied in the peer-reviewed literature across the pathways described in the research overview above. Velox Peptides supplies Tesamorelin strictly as a research reagent for in vitro use by qualified researchers. It is not a medicinal product and is not for human or veterinary consumption.
What is the CAS number for Tesamorelin?
The CAS registry number for Tesamorelin is 218949-48-5.
Is Tesamorelin legal to buy in the UK?
Yes. Tesamorelin is lawful to purchase in the United Kingdom strictly for legitimate in vitro scientific research purposes. It is not a controlled substance under UK law and is not subject to prescription requirements when purchased for research use. Velox Peptides supplies Tesamorelin solely as a research reagent to qualified researchers. Buyers are responsible for ensuring all use complies with applicable law and with Velox Peptides’ Research Use Policy.
How does Tesamorelin compare to CJC-1295 wo DAC as a research compound?
Both are GHRH receptor agonists that stimulate GH release, but they differ in length and structure. Tesamorelin is the full 44-amino-acid GHRH sequence with an N-terminal trans-3-hexenoic acid modification for stability, while CJC-1295 wo DAC is the shorter 30-amino-acid GHRH(1-29) fragment with amino acid substitutions for enzymatic resistance. Tesamorelin more closely approximates native GHRH structure; CJC-1295 wo DAC is a shorter, modified fragment. Research teams choose between them based on the specific GHRH receptor pharmacology they are investigating and the half-life profile required by their experimental design.
How quickly is my order dispatched and delivered?
Orders placed before 2pm on a working day are dispatched the same day via Royal Mail Tracked 24, typically arriving in 1–2 working days, with tracking emailed on dispatch. UK shipping is free over £100, and EU shipping is available.
How do I pay, and is it secure?
We accept Pay by Bank - an instant, secure open-banking payment via Fena, where you authorise the payment in your own banking app and no card details are stored on our site. Manual UK bank transfer is available as a fallback. Orders are dispatched within 24 hours of cleared payment.
Does my order include a certificate of analysis?
Yes. Every order includes a batch-specific Certificate of Analysis documenting third-party HPLC purity and mass-spectrometry identity confirmation, emailed with your order confirmation. Previous batch CoAs are archived in our CoA library.
Compliance notice
For in vitro research use only. Tesamorelin is supplied solely as a research reagent for qualified professionals conducting in vitro or animal-model studies. It is not a medicinal product within the meaning of the Human Medicines Regulations 2012. It has not been evaluated by the MHRA or FDA. It is not intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale.
